Last updated: October 2, 2026
Mometasone furoate monohydrate is a mature, highly potent corticosteroid with commercial opportunities in nasal, inhaled, topical, and combination products. The strongest opportunities are differentiated delivery systems, preservative-free formulations, device-compatible products, pediatric presentations, and low-cost regional generics. Excipient selection must control hydrate state, particle size, dose uniformity, suspension stability, skin deposition, aerosol performance, and microbial preservation.
What pharmaceutical products contain mometasone furoate monohydrate?
Mometasone furoate is marketed in several dosage forms. The monohydrate is particularly relevant to aqueous nasal suspensions and inhaled products where solid-state control affects dose delivery and stability.
| Product category |
Representative product |
Route |
Primary commercial issue |
| Nasal spray |
Nasonex |
Intranasal |
Suspension uniformity, plume geometry, preservative strategy |
| Topical cream |
Elocon and generics |
Dermal |
Skin penetration, sensory profile, corticosteroid potency |
| Topical ointment |
Elocon and generics |
Dermal |
Occlusion, deposition, patient acceptability |
| Topical lotion |
Elocon lotion and generics |
Dermal |
Spreadability, scalp use, low residue |
| Inhaled powder |
Asmanex Twisthaler |
Pulmonary |
Lactose carrier, powder dispersion, device resistance |
| Metered-dose inhaler |
Asmanex HFA |
Pulmonary |
Aerosol particle size, valve compatibility, propellant stability |
| Combination nasal products |
Mometasone plus antihistamines |
Intranasal |
Combination suspension and regulatory bridging |
FDA labeling identifies mometasone furoate monohydrate as the active ingredient in Nasonex, with the labeled quantity expressed as the equivalent amount of anhydrous mometasone furoate [1]. That distinction affects assay calculations, raw-material specifications, and regulatory comparability.
What excipients are used in mometasone furoate products?
Excipients differ substantially by route because the formulation objective changes from skin deposition to nasal residence or pulmonary delivery.
Nasal suspension excipients
Nasonex uses a water-based suspension containing glycerin, microcrystalline cellulose, carboxymethylcellulose sodium, polysorbate 80, benzalkonium chloride, citric acid, sodium citrate, and purified water [1].
The excipient functions are:
| Excipient or excipient class |
Function in nasal formulation |
| Microcrystalline cellulose and carboxymethylcellulose sodium |
Suspending and rheology-modifying system |
| Glycerin |
Tonicity adjustment and moisture retention |
| Polysorbate 80 |
Wetting and dispersion of hydrophobic drug particles |
| Citric acid and sodium citrate |
Buffering and pH control |
| Benzalkonium chloride |
Antimicrobial preservation |
| Purified water |
Continuous phase |
The commercial challenge is not simple solubilization. Mometasone furoate has very low aqueous solubility, so the nasal product is a micronized suspension. Critical quality attributes include particle-size distribution, sedimentation, redispersibility, delivered dose uniformity, spray content uniformity, plume geometry, droplet-size distribution, and pump reproducibility.
Topical cream excipients
Mometasone furoate cream products commonly use propylene glycol stearate, stearyl alcohol, ceteareth-20, hexylene glycol, titanium dioxide, white wax, petrolatum, aluminum starch octenylsuccinate, phosphoric acid, and purified water [2].
This system combines an emulsion base with emollient and absorbent components. Aluminum starch octenylsuccinate can reduce greasiness and improve skin feel. Propylene glycol derivatives support spreading and may influence drug partitioning into the stratum corneum.
Commercially attractive reformulation targets include:
- Lower-residue creams for facial and intertriginous use.
- Silicone-free and mineral-oil-reduced systems.
- Preservative systems with improved tolerability.
- Airless pump packaging to reduce contamination.
- Foam or gel systems for scalp and hairy skin.
- Higher patient-acceptance formulations with faster rub-in.
Topical ointment excipients
Ointment products generally use a hydrocarbon base with waxes and a small amount of penetration-supporting excipient. Representative excipients include white petrolatum, white wax, hydroxypropyl cellulose, hexylene glycol, and propylene glycol stearate [3].
Ointments offer high occlusion and strong skin deposition but can have poor cosmetic acceptance. The most practical opportunity is not simply a new excipient. It is a formulation that retains therapeutic equivalence while reducing tack, shine, and transfer to clothing.
Topical lotion excipients
Mometasone lotion products use water, isopropyl alcohol, hydroxypropyl cellulose, sodium phosphate monobasic, and phosphoric acid [4].
The alcohol-containing vehicle supports rapid evaporation and scalp application. Commercial differentiation can come from reduced stinging, lower odor, improved sprayability, and compatibility with multidose scalp applicators.
Inhaled-product excipients
Asmanex Twisthaler uses lactose as a carrier in a dry-powder inhaler, while Asmanex HFA uses hydrofluoroalkane propellant with ethanol and oleic acid [5,6].
The inhaled route creates a high technical barrier. The formulation must maintain aerodynamic performance over the product shelf life and across humidity conditions. The key variables are:
- Micronized drug particle size.
- Carrier lactose grade and surface morphology.
- Drug-carrier adhesion.
- Device resistance.
- Metering-system consistency.
- Fine-particle fraction.
- Moisture uptake.
- Dose uniformity after storage.
How should an excipient strategy be designed for mometasone furoate monohydrate?
A successful strategy begins with route-specific control of the active pharmaceutical ingredient rather than with broad excipient screening.
Control the hydrate and solid-state form
Mometasone furoate monohydrate should be specified by crystal form, water content, thermal behavior, particle-size distribution, morphology, and surface area. Hydrate loss or conversion during milling, drying, or storage can affect assay, density, suspension behavior, and inhalation performance.
Recommended development controls include:
| Attribute |
Strategic purpose |
| XRPD pattern |
Confirm solid-state identity |
| Karl Fischer water content |
Control hydrate state |
| DSC or TGA |
Detect dehydration and thermal transitions |
| Laser diffraction |
Control bulk particle-size distribution |
| Microscopy |
Assess shape, agglomeration, and morphology |
| Specific surface area |
Support wetting and dissolution assessment |
| Residual solvents |
Control manufacturing consistency |
For nasal and inhaled products, particle-size control is central. For topical products, particle size still matters, but vehicle structure and skin partitioning often have greater commercial impact.
Select excipients by delivery objective
For nasal suspension products, the preferred platform is a structured aqueous vehicle with controlled yield stress. Too little viscosity increases sedimentation; too much viscosity can impair spray performance and patient use.
For inhaled products, lactose carrier engineering and device matching are more important than conventional solubility enhancement. Liquid or semi-solid excipients generally are not appropriate for a dry-powder product.
For topical products, the best commercial platform depends on the body site:
| Body site |
Preferred formulation attributes |
| Scalp |
Low residue, fast drying, spray or lotion delivery |
| Face |
Low irritation, low shine, reduced occlusion |
| Trunk and limbs |
Cream or ointment with strong deposition |
| Intertriginous areas |
Low-grease, low-occlusion vehicle |
| Pediatric skin |
Minimal irritants, preservative control, easy dosing |
What formulations are protected by mometasone patents?
The basic composition-of-matter protection for mometasone furoate is expired, allowing extensive generic development. Current commercial protection is more likely to arise from formulation, delivery device, combination, manufacturing, or method-of-use claims.
Potentially relevant claim categories include:
- Aqueous nasal suspensions with defined rheology and particle-size ranges.
- Metered nasal spray pumps with specific plume or droplet characteristics.
- Inhalation powders using selected lactose grades and device geometries.
- HFA aerosol formulations with defined propellant, ethanol, and surfactant ratios.
- Topical emulsions, foams, gels, lotions, and low-residue vehicles.
- Combination products containing mometasone and an antihistamine.
- Methods for treating allergic rhinitis, asthma, dermatitis, or other inflammatory disorders.
- Manufacturing processes controlling micronization, blending, filling, or suspension aging.
The relevant patent position is product-specific. A generic cream may face a different patent profile from a generic nasal suspension or inhaler. The FDA Orange Book remains the principal source for listed patents associated with approved prescription products, but Orange Book listings do not capture every formulation or device right that could affect market entry [7].
When does mometasone furoate lose exclusivity?
Mometasone furoate has already lost its core small-molecule exclusivity. The commercial question is no longer whether generic entry is legally possible. It is whether a new entrant can satisfy route-specific bioequivalence, device, chemistry, manufacturing, and quality requirements at a competitive cost.
| Exclusivity element |
Current commercial position |
| Basic active ingredient |
Expired |
| Conventional topical products |
Generic competition established |
| Nasal spray |
Generic competition established in the U.S. |
| Dry-powder inhaler |
More technically difficult because of device and aerodynamic requirements |
| HFA inhaler |
More difficult because of formulation-device integration |
| Combination products |
May retain formulation, clinical, or regulatory barriers |
| New delivery formats |
Potentially protectable through patents and regulatory exclusivity |
FDA-approved generic mometasone nasal sprays demonstrate that the nasal route can be entered through an abbreviated new drug application when the sponsor can match the reference product's quality and performance attributes [8]. Topical products can use the ANDA pathway when pharmaceutical equivalence and bioequivalence requirements are met. Complex inhaled products may require more extensive comparative performance work.
Is there biosimilar risk for mometasone furoate?
No. Mometasone furoate is a chemically synthesized small molecule, not a biologic. Biosimilar regulation under the Public Health Service Act does not apply.
The relevant competitive risks are:
- ANDA-approved generics.
- Authorized generics.
- Private-label topical products.
- OTC or behind-the-counter allergy alternatives.
- Combination nasal sprays.
- Other inhaled corticosteroids, including fluticasone, budesonide, and beclomethasone.
- Nonsteroidal topical products such as calcineurin inhibitors and phosphodiesterase-4 inhibitors.
What FDA regulatory barriers affect commercial entry?
The regulatory burden depends on dosage form.
Nasal spray
A nasal generic must demonstrate pharmaceutical equivalence and comparable in vitro and, where required, in vivo performance. Key tests include delivered dose, spray content uniformity, droplet-size distribution, plume geometry, priming and repriming, microbial quality, and device robustness.
Topical products
Topical mometasone products can face requirements for comparative physicochemical characterization, in vitro release testing, and skin permeation or pharmacodynamic equivalence. Product performance can be sensitive to changes in emulsifier, preservative, particle size, and manufacturing shear.
Dry-powder inhalers
Inhaled products require aerodynamic particle-size distribution, emitted dose, fine-particle dose, device resistance, moisture stability, and batch-to-batch consistency. A lactose carrier change can materially affect lung deposition even when the nominal drug strength is unchanged.
HFA metered-dose inhalers
HFA products require compatibility among the drug, propellant, ethanol, oleic acid, valve, actuator, canister, and manufacturing process. Extractables, leachables, suspension stability, valve delivery, and plume geometry are commercial gating items.
Which commercial opportunities are most attractive?
Preservative-free nasal products
Benzalkonium chloride remains a differentiating target for patients and prescribers concerned about chronic nasal use. A preservative-free multidose system would require an appropriate microbial-control architecture, such as a validated valve or airless delivery system. The opportunity is strongest where chronic allergic rhinitis use and premium pricing support device costs.
Combination nasal sprays
Mometasone combined with an antihistamine can compete against established combination products. The technical challenge is maintaining suspension stability and dose uniformity for two active ingredients with different particle and wetting characteristics.
Pediatric and low-waste delivery
Opportunities include:
- Smaller bottle sizes.
- Dose counters.
- Child-resistant but easy-to-use actuators.
- Reduced priming waste.
- Low-residual-volume pumps.
- Improved tactile and visual dose feedback.
These features may support device patents and differentiated branding even when the active ingredient is generic.
Premium topical formats
Foams, gels, sprays, and low-residue lotions can command better commercial positioning than conventional creams and ointments. The strongest targets are scalp disease, steroid-sensitive body areas, and patients who discontinue treatment because of greasiness or transfer.
Regional generic manufacturing
Mometasone products have broad geographic demand because allergic rhinitis, asthma, eczema, and psoriasis are large chronic markets. Local manufacturing can reduce freight, improve tender competitiveness, and support country-specific registrations. The most scalable products are conventional creams, lotions, ointments, and nasal sprays. Inhaled products require higher capital and device-engineering capability.
How does mometasone compare with competing corticosteroids?
| Attribute |
Mometasone furoate |
Fluticasone propionate |
Budesonide |
Beclomethasone dipropionate |
| Main commercial routes |
Nasal, topical, inhaled |
Nasal, inhaled, topical in selected markets |
Nasal, inhaled, nebulized |
Nasal, inhaled |
| Generic maturity |
High for topical and nasal products |
High |
High |
High |
| Formulation complexity |
High for nasal and inhaled products |
High |
Moderate to high |
High in aerosol products |
| Topical potency positioning |
High |
High |
Moderate to high |
High |
| Device differentiation |
Important |
Important |
Important |
Important |
| Biosimilar exposure |
None |
None |
None |
None |
Mometasone's commercial strength is its broad route coverage and established physician familiarity. Its weakness is the limited room for differentiation in conventional generic products. Value is concentrated in delivery systems, combinations, and patient-acceptance improvements.
What patent litigation and Paragraph IV risks exist?
Paragraph IV risk is concentrated in active patents listed against specific reference products, particularly newer combinations, inhalers, and device-linked products. Conventional mometasone cream and nasal-spray competition is more likely to involve routine ANDA entry than major litigation.
A generic sponsor should review:
- Orange Book-listed patents for the relevant reference product.
- Patent term extension and pediatric exclusivity.
- Formulation and device patents.
- Method-of-use claims.
- Declaratory-judgment and infringement litigation.
- Settlement agreements that delay launch.
- Non-patent regulatory exclusivities.
- State and federal product-liability exposure.
A Paragraph IV certification can trigger a 45-day infringement action and potentially a 30-month stay under the Hatch-Waxman framework, subject to statutory exceptions [9]. Settlement agreements should be assessed for launch date, authorized-generic provisions, supply obligations, and restrictions on alternative formulations.
What manufacturing and intellectual-property barriers matter most?
The highest barriers are process and product-performance barriers rather than active-ingredient synthesis.
Key manufacturing risks include:
- Drug agglomeration during micronization.
- Hydrate conversion during drying or storage.
- Inconsistent suspension rheology.
- Inadequate wetting of hydrophobic particles.
- Blend segregation in dry-powder inhalers.
- Moisture sensitivity of lactose-based powders.
- Valve and actuator variability.
- Microbial contamination in aqueous products.
- Preservative incompatibility.
- Scale-up changes in emulsion droplet size.
A defensible IP position can combine composition claims with process controls, device geometry, particle-size distributions, and performance specifications. Formulations that rely only on conventional excipient substitutions are more vulnerable to design-around and may receive limited commercial protection.
What is the commercial outlook for mometasone furoate products?
Mometasone is a mature molecule with durable demand but limited opportunity for undifferentiated products. The most attractive strategies are:
- A preservative-free nasal suspension with a validated multidose device.
- A mometasone-antihistamine combination with strong suspension control.
- A low-residue topical foam, gel, or scalp spray.
- A cost-optimized generic nasal spray for emerging markets.
- A device-matched inhaled product where the sponsor has powder and actuator expertise.
- Contract manufacturing of topical dosage forms for regional brands.
Revenue exposure is greatest in chronic allergic rhinitis, asthma maintenance, and recurring dermatology treatment. Price erosion will be substantial in standard generics. Premium pricing requires a measurable improvement in adherence, tolerability, convenience, device performance, or combination therapy.
Key Takeaways
- Mometasone furoate monohydrate is a mature small molecule with no biosimilar pathway.
- The core composition-of-matter protection has expired.
- Excipient strategy must be route-specific: suspension rheology for nasal products, vehicle-skin interaction for topical products, and powder-device integration for inhalers.
- Preservative-free nasal delivery and low-residue topical formats offer the clearest differentiation.
- Inhaled products have higher technical and regulatory barriers than creams, ointments, lotions, and nasal sprays.
- Orange Book review, device patent analysis, and Paragraph IV assessment remain necessary for product-specific launch planning.
- Commercial value depends on delivery performance and patient acceptance more than on a new excipient alone.
FAQs
Can mometasone furoate monohydrate be formulated as a solution?
Usually not as a conventional aqueous solution because mometasone furoate has very low water solubility. Suspension, emulsion, cosolvent, or specialized vehicle approaches are more practical.
Which excipient is most important in a mometasone nasal spray?
The suspending and rheology-modifying system is usually the most important because it controls sedimentation, redispersibility, delivered dose, and spray performance. Microcrystalline cellulose and carboxymethylcellulose sodium are representative choices [1].
Is benzalkonium chloride required in mometasone nasal spray?
No. It is used in established multidose products, but a preservative-free design may use a validated microbial-control device and manufacturing strategy.
Can lactose be replaced in a mometasone dry-powder inhaler?
Potentially, but carrier replacement can change dispersion, fine-particle dose, moisture sensitivity, and device performance. It would require comparative aerodynamic and stability data.
Which mometasone dosage form has the lowest development risk?
Conventional topical cream, ointment, or lotion generally has lower development risk than nasal, dry-powder inhaled, or HFA inhaled products. Nasal products are commercially larger but require tighter control of device and suspension attributes.
References
-
U.S. Food and Drug Administration. (2023). Nasonex 50 mcg nasal spray: Prescribing information. Merck Sharp & Dohme LLC.
-
U.S. Food and Drug Administration. (2023). Elocon cream 0.1%: Prescribing information. Organon & Co.
-
U.S. Food and Drug Administration. (2023). Elocon ointment 0.1%: Prescribing information. Organon & Co.
-
U.S. Food and Drug Administration. (2023). Elocon lotion 0.1%: Prescribing information. Organon & Co.
-
U.S. Food and Drug Administration. (2023). Asmanex Twisthaler: Prescribing information. Organon & Co.
-
U.S. Food and Drug Administration. (2023). Asmanex HFA: Prescribing information. Organon & Co.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
-
U.S. Food and Drug Administration. (2024). Product-specific guidances for generic drug development. FDA.
-
U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. ยง 355(j).
